共 151 条
[1]
Ciechanover A(1994)The ubiquitin–proteasome proteolytic pathway Cell 79 13-21
[2]
Orlowski RZ(2008)Proteasome inhibitors in cancer therapy: lessons from the first decade Clin Cancer Res 14 1649-1657
[3]
Kuhn DJ(2004)The development of proteasome inhibitors as anticancer drugs Cancer Cells 5 417-421
[4]
Adams J(2006)The proteasome: a novel target for anticancer therapy Clin Transl Oncol 8 313-317
[5]
Montagut C(2003)A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609-2617
[6]
Rovira A(2006)Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma Curr Opin Oncol 18 598-608
[7]
Albanell J(2008)Bortezomib: a novel chemotherapeutic agent for hematologic malignancies Am J Health Syst Pharm 65 1221-1231
[8]
Richardson PG(2009)Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma Br J Haematol 146 652-655
[9]
Barlogie B(2009)Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial Br J Haematol 145 34-39
[10]
Berenson J(2009)Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study Ann Oncol 20 520-525